Tham Muly, Tan Kar Wai, Keeble Jo, Wang Xiaojie, Hubert Sandra, Barron Luke, Tan Nguan Soon, Kato Masashi, Prevost-Blondel Armelle, Angeli Veronique, Abastado Jean-Pierre
Singapore Immunology Network, BMSI, A-STAR, Singapore.
Singapore Immunology Network, BMSI, A-STAR, Singapore. Department of Clinical Research, Singapore General Hospital, Singapore.
Oncotarget. 2014 Dec 15;5(23):12027-42. doi: 10.18632/oncotarget.2482.
M2 macrophages promote tumor growth and metastasis, but their interactions with specific tumor cell populations are poorly characterized. Using a mouse model of spontaneous melanoma, we showed that CD34- but not CD34+ tumor-initiating cells (TICs) depend on M2 macrophages for survival and proliferation. Tumor-associated macrophages (TAMs) and macrophage-conditioned media protected CD34- TICs from chemotherapy in vitro. In vivo, while inhibition of CD115 suppressed the macrophage-dependent CD34- TIC population, chemotherapy accelerated its development. The ability of TICs to respond to TAMs was acquired during melanoma progression and immediately preceded a surge in metastatic outgrowth. TAM-derived transforming growth factor-β (TGFβ) and polyamines produced via the Arginase pathway were critical for stimulation of TICs and synergized to promote their growth.
J Immunother Cancer. 2019-11-27
Front Immunol. 2024-12-5
Cancer Lett. 2023-10-28
Cancer Cell Int. 2023-7-31
Brain Behav Immun Health. 2020-5-21
Front Cell Dev Biol. 2021-5-20
Cancer Cell. 2013-2-11
J Clin Invest. 2013-2-8
Cell Stem Cell. 2012-12-7